Injection of denosumab-desu biosimilar (Osvyrti/Jubereq), billed per 1 mg administered

This code represents a biosimilar to the reference product denosumab (Prolia/Xgeva), specifically the biosimilar marketed as Osvyrti or Jubereq. Denosumab is a RANK ligand inhibitor (monoclonal antibody) that reduces osteoclast-mediated bone resorption. It is administered via subcutaneous injection and is used to manage conditions involving pathologic bone loss or skeletal-related events.

Report this code when the biosimilar denosumab-desu is administered for indications such as postmenopausal osteoporosis, bone loss in oncology patients (e.g., prevention of skeletal-related events in solid tumors or multiple myeloma with bone metastases), or glucocorticoid-induced osteoporosis. Billing is per 1 mg, so units must reflect the total dose administered (e.g., a 60 mg dose = 60 units; 120 mg dose = 120 units). Documentation should include the specific product name/NDC, dose administered, and clinical indication.

• Do not interchange with the reference product codes (J0897 for Prolia/Xgeva); payers may require the biosimilar-specific code when the biosimilar is dispensed, and substitution of codes can result in claim denial or compliance issues.
• Verify NDC reporting requirements: Many payers, including Medicare Part B, require the NDC on the claim line to confirm the specific biosimilar product billed; failure to include the NDC is a common denial trigger.
• Confirm payer coverage policy: Some payers may require prior authorization or step therapy documentation (e.g., failure of bisphosphonates) before covering denosumab biosimilars, and the indication (osteoporosis vs. oncology) may affect which benefit category applies.